Home Newsfeeds Wolfe Research Maintains Underperform on DocuSign, Raises Price Target to $53

Wolfe Research Maintains Underperform on DocuSign, Raises Price Target to $53

Wolfe Research analyst Alex Zukin maintains DocuSign (NASDAQ:DOCU) with a Underperform and raises the price target from $50 to $53.

byBenzinga Newsdesk

September 12, 2022

1 minute read

Wolfe Research analyst Alex Zukin maintains DocuSign (NASDAQ:DOCU) with a Underperform and raises the price target from $50 to $53.

Tencent Clocks First Quarterly Revenue Decline As China’s Tech Crackdown, Macro Slowdown Weighs

By Anusuya Lahiri

August 17, 8:34 AM

Tencent Holding Ltd (OTC:TCEHY) registered its first-ever revenue decline after its workforce shrank almost 5%, Bloomberg reports. The first-quarter FY22…

BABA

Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS

By Vandana Singh

January 19, 11:50 AM

Neuronetics Inc (NASDAQ:STIM) and Greenbrook TMS Inc (NASDAQ:GBNH) announced an expanded commercial partnership through year-end 2028. Under the partnership agreement, Neuronetics will…

GBNH

Barclays Initiates Coverage On Volta with Equal-Weight Rating, Announces Price Target of $2

By Benzinga Newsdesk

August 5, 4:45 AM

Barclays analyst Christine Cho initiates coverage on Volta (NYSE:VLTA) with a Equal-Weight rating and announces Price Target of $2.

VLTA

Lumos Pharma Announces New Data And Analysis Of 15 Subjects From OraGrowtH212 Trial Presented At The 2023 ESPE Annual Meeting

By Benzinga Newsdesk

September 26, 9:20 AM

Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal ChildrenAnalysis Shows Annualized Height Velocity Increased ~62% Compared to BaselineData Support LUM-201 Mechanism of

LUMO

Wolfe Research Maintains Underperform on DocuSign, Raises Price Target to $53

Related Posts

Tencent Clocks First Quarterly Revenue Decline As China’s Tech Crackdown, Macro Slowdown Weighs

Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS

Barclays Initiates Coverage On Volta with Equal-Weight Rating, Announces Price Target of $2

Lumos Pharma Announces New Data And Analysis Of 15 Subjects From OraGrowtH212 Trial Presented At The 2023 ESPE Annual Meeting